Altimmune (ALT)
(Delayed Data from NSDQ)
$6.58 USD
-0.17 (-2.52%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $6.57 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ALT 6.58 -0.17(-2.52%)
Will ALT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALT
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
ALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
Other News for ALT
Altitude Group Reports Record Financial Growth
Altitude Group Schedules Interactive Investor Presentation
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune announces publication of study of pemvidutide in MASLD
Viking sends Lilly, Novo lower as obesity drug enters late-stage program